Canadian radioisotope developer MDS Nordion, a division of Toronto-based MDS, reported an 11% gain in revenues for its fiscal 2006 second quarter (end-April 30).
For the period, revenue grew to $83 million Canadian ($74 million U.S.), compared with $75 million ($67 million) in the same period last year.
Results for its medical imaging business were positively impacted as it stepped in to offset supply shortages related to a competitor's voluntary recall of technetium generators, according to the Kanata, Ontario-based firm.
By AuntMinnie.com staff writers
June 8, 2006
Related Reading
MDS Nordion moves closer to end users, June 7, 2006
MDS Nordion, Molecular Insight Pharmaceuticals partner, February 16, 2006
MDS Nordion collaborates with GSK, November 27, 2005
MDS Nordion to supply yttrium-90 to Berlex, September 20, 2005
MDS Nordion targets drug discovery, June 28, 2005
Copyright © 2006 AuntMinnie.com
